Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Myelodysplastic Syndromes and Ash 2020

View overview page
5:13
alloHCT: HLA-matched unrelated vs HLA-identical sibling donor for MDS
Guru Subramanian Guru Murthy • 17 Dec 2020
5:37
Allogeneic cord blood Treg infusion for BMF syndromes
Tapan Kadia • 3 Dec 2020
3:18
Allogeneic CAR-NK cell therapy in R/R AML/MDS
Carlos Bachier • 3 Dec 2020
1:26
RIC allogeneic HCT for high-risk MDS
Corey Cutler • 15 Jan 2021
1:17
Using an animated patient’s guide to improve understanding of MDS
David Sallman • 10 Dec 2020
3:51
Venetoclax plus azacitidine in treatment-naïve and R/R MDS
Amer Zeidan • 7 Dec 2020
1:53
First-in-human trial of rapidly manufactured UltraCAR T-cells in R/R myeloid malignancies
David Sallman • 10 Dec 2020
3:12
Worldwide access to efficacious agents in MDS needs improvement
Amer Zeidan • 7 Dec 2020
7:32
Current immune checkpoint inhibitor trials in AML/MDS
Amer Zeidan • 7 Dec 2020
2:19
Imetelstat for transfusion-dependent R/R MDS
Uwe Platzbecker • 17 Dec 2020
2:00
NKG2D CAR-T cell therapy in AML/MDS
David Sallman • 10 Dec 2020
2:29
MEDALIST: luspatercept and erythropoiesis biomarkers in MDS
Uwe Platzbecker • 17 Dec 2020
6:58
Venetoclax plus azacitidine for higher-risk MDS
Jacqueline Garcia • 9 Dec 2020
9:46
Venetoclax prior to allo-HCT for high-risk myeloid malignancies
Jacqueline Garcia • 4 Dec 2020
8:35
Effect of BMT status on decitabine plus ipilimumab in R/R MDS/AML
Jacqueline Garcia • 4 Dec 2020
2:11
SY-1425 plus azacitidine treatment in AML
Thomas Cluzeau • 9 Dec 2020

The MDS Channel on VJHemOnc is supported by Bristol Myers Squibb,Geron and Syros Pharmaceuticals.

This supporter has no influence over the production of the content.

If you are interested in becoming a supporter of The MDS Channel, please contact us.

VJHemOnc is pleased to be media partners with the MDS Foundation, visit their website to learn more.

The content of VJHemOnc is intended for healthcare professionals